Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid.

ABSTRACT:

Background

Conventional systemic corticosteroid therapy for bullous pemphigoid (BP) has been challenged due to severe adverse events. Dupilumab has emerged as an alternative therapeutical option of BP patients.

Objectives

To evaluate the efficacy of dupilumab monotherapy and the combination with medium/low-dose corticosteroids for BP treatment.

Methods

Thirteen, twenty-four and thirty-two BP patients treated with Dupilumab monotherapy (Dupi group), dupilumab combined with corticosteroids (Dupi + CS group), and corticosteroid monotherapy (CS group), respectively, were retrospectively analyzed for various clinical and laboratory parameters.

Results

In the Dupi group, the total Bullous Pemphigoid Disease Area Index (BPDAI) Total, Erosion/Blister, Urticaria/Erythem

SUBMITTER: Liang G 

PROVIDER: S-EPMC11962819 | biostudies-literature | 2025 Mar-Apr

REPOSITORIES: biostudies-literature